Teva/Allergan Generics: An unprecedented generics merger* In a nutshell While the Commission has had significant experience dealing with mergers in the generic medicines industry, the sheer scale of Teva/Allergan Generics, combining two of the top four players globally, posed a number of interesting challenges. The Commission assessed competitive dynamics beyond product-by-product overlaps at the level of the overall sale of generics in a Member State, and identified serious doubts in the UK, Ireland and Iceland. For the first time, it deemed certain vertical aspects of a generics transaction problematic. Finally, the remedy design and monitoring also brought their share of complexity, requiring innovative ad hoc approaches. 1. Overview In March 2016, the Commission cleared the
Share on
|
|
The EU Commission clears acquisition of a fourth largest global manufacturer of generic medicines by the largest global competitor, subject to complex remedies and monitoring, including addressing concerns about vertical relationships between parties for the first time in a generics merger (Teva / Allergan Generics)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
